Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Codexis, Inc.✕ CDXS · #17,521 in the world | Pharmicell Co., Ltd.✕ 005690.KS · #12,422 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇰🇷 South Korea |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2002 | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Codexis, Inc. | Pharmicell Co., Ltd. |
|---|---|---|
| 2025 | $70 MSEC | — |
| 2024 | $59 MSEC | — |
| 2023 | $70 MSEC | — |
| 2022 | $139 MSEC | — |
| 2021 | $105 MSEC | — |
| 2020 | $69 MSEC | — |
| 2019 | $68 MSEC | — |
| 2018 | $61 MSEC | — |
| 2017 | $50 MSEC | — |
| 2016 | $49 MSEC | — |
| 2015 | $42 MSEC | — |
| 2014 | $35 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $140 M |
| $514 M |
| Revenue | $70 M | — |
|---|
| Net income | $-44 M | — |
|---|
| Employees | 261 | — |
|---|
| Valuation | ||
|---|---|---|
| Price to sales | 1.6× | — |
| Price to book | 2.8× | — |
| Free cash flow yield | -17.0% | — |
| Profitability | ||
|---|---|---|
| Gross margin | 86.7% | — |
| Operating margin | -59.3% | — |
| Net margin | -62.5% | — |
| Return on equity | -74.9% | — |
| Growth | ||
|---|---|---|
| Revenue growth | 18.6% | — |
| Revenue growth, 3 years a year | -20.2% | — |
| Financial strength | ||
|---|---|---|
| Debt to equity | 0.8× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | -33.9% | — |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | 4 of 9 | — |
| Altman Z-score zone | distress | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Aug 2026 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.